-
iShares U.S. Medical Devices ETF (IHI $61.43)
- $61.43 P/E (TTM): 105.73X Cap: $4.40B
- View IHI Profile
- View Questions on IHI
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
Health Care Select Sector SPDR (XLV $136.48)
- $136.48 P/E (TTM): 65.74X Cap: $33.71B
- View XLV Profile
- View Questions on XLV
-
iShares U.S. Medical Devices ETF (IHI $61.43)
- $61.43 P/E (TTM): 105.73X Cap: $4.40B
- View IHI Profile
- View Questions on IHI
Q: Health care as a sector has me puzzled. I was adding to my positions in XLV and IHI during 2023-2024. I was prompted to keep investing thinking demographics would favor growth; that elective medical procedures postponed would come roaring back in the years following Covid. Mostly good companies were held in the above ETFs, and I was comfortable investing also because of familiarity with products and services. Markets have proven me wrong. My cost base is markedly higher than valuations today. XLV is down ~5.25% over the past 12 months (year-to-date return is flat —down -0.05%).IHI, although slightly up ~4.28% YTD, has still not recovered from a 20% drop in 2022. (Losses I show are much greater and are not useable for tax).
Current officials in the US admin have no clue on how to go about drug price reforms. Worse: they don’t know that they have no clue. Reforms are necessary; and PBMs are rightly under scrutiny for opaque pricing practices. I say this notwithstanding that UNH has produced the largest dollar loss I have had in several years.
The science and med professionals who DO know how to implement sensible and substantial changes are fired and replaced by sycophantic, subservient ignorant types. Is it therefore prudent now to sell one or both of XLV and IHI and redeploy cash in other areas? OR, would one be giving up at possibly the exact wrong time? Is now finally the time that patience with XLV and IHI has a greater chance of paying off?
Current officials in the US admin have no clue on how to go about drug price reforms. Worse: they don’t know that they have no clue. Reforms are necessary; and PBMs are rightly under scrutiny for opaque pricing practices. I say this notwithstanding that UNH has produced the largest dollar loss I have had in several years.
The science and med professionals who DO know how to implement sensible and substantial changes are fired and replaced by sycophantic, subservient ignorant types. Is it therefore prudent now to sell one or both of XLV and IHI and redeploy cash in other areas? OR, would one be giving up at possibly the exact wrong time? Is now finally the time that patience with XLV and IHI has a greater chance of paying off?
-
Gilead Sciences Inc. (GILD $116.20)
- $116.20 P/E (TTM): 23.78X Cap: $144.54B
- View GILD Profile
- View Questions on GILD
-
Intuitive Surgical Inc. (ISRG $495.86)
- $495.86 P/E (TTM): 71.54X Cap: $177.75B
- View ISRG Profile
- View Questions on ISRG
-
AbbVie Inc. (ABBV $190.28)
- $190.28 P/E (TTM): 81.55X Cap: $336.11B
- View ABBV Profile
- View Questions on ABBV
-
Johnson & Johnson (JNJ $168.30)
- $168.30 P/E (TTM): 18.86X Cap: $405.32B
- View JNJ Profile
- View Questions on JNJ
-
Eli Lilly and Company (LLY $812.69)
- $812.69 P/E (TTM): 65.54X Cap: $770.21B
- View LLY Profile
- View Questions on LLY
-
Medtronic plc. (MDT $92.94)
- $92.94 P/E (TTM): 25.57X Cap: $119.08B
- View MDT Profile
- View Questions on MDT
-
Stryker Corporation (SYK $403.53)
- $403.53 P/E (TTM): 53.6X Cap: $154.21B
- View SYK Profile
- View Questions on SYK
-
Thermo Fisher Scientific Inc (TMO $478.32)
- $478.32 P/E (TTM): 27.86X Cap: $180.56B
- View TMO Profile
- View Questions on TMO
-
Health Care Select Sector SPDR (XLV $136.48)
- $136.48 P/E (TTM): 65.74X Cap: $33.71B
- View XLV Profile
- View Questions on XLV
-
iShares U.S. Medical Devices ETF (IHI $61.43)
- $61.43 P/E (TTM): 105.73X Cap: $4.40B
- View IHI Profile
- View Questions on IHI
-
Sabra Health Care REIT Inc. (SBRA $18.22)
- $18.22 P/E (TTM): 30.93X Cap: $4.33B
- View SBRA Profile
- View Questions on SBRA
-
Healthcare Realty Trust Incorporated (HR $16.12)
- $16.12 Cap: $5.66B
- View HR Profile
- View Questions on HR
-
iShares U.S. Pharmaceuticals ETF (IHE $69.27)
- $69.27 P/E (TTM): 57.72X Cap: $568M
- View IHE Profile
- View Questions on IHE
-
Catalyst Pharmaceuticals Inc. (CPRX $20.97)
- $20.97 P/E (TTM): 13.39X Cap: $2.55B
- View CPRX Profile
- View Questions on CPRX
Q: There was an article in the Globe and Mail today by David Rosenberg about the aging population and he suggested health care related investments such as health care REITS, pharma, devices, and services. What do you think of this idea and can you give me a few recommendations in canada and the US for each of the 4 categories (health reits, pharma, devices, sefrvices)? A mix of ETFS and individual stocks would be great.
-
Intuitive Surgical Inc. (ISRG $495.86)
- $495.86 P/E (TTM): 71.54X Cap: $177.75B
- View ISRG Profile
- View Questions on ISRG
-
Abbott Laboratories (ABT $126.54)
- $126.54 P/E (TTM): 16.32X Cap: $220.15B
- View ABT Profile
- View Questions on ABT
-
Becton Dickinson and Company (BDX $185.32)
- $185.32 P/E (TTM): 35.59X Cap: $53.11B
- View BDX Profile
- View Questions on BDX
-
Boston Scientific Corporation (BSX $106.14)
- $106.14 P/E (TTM): 77.53X Cap: $157.02B
- View BSX Profile
- View Questions on BSX
-
iShares U.S. Medical Devices ETF (IHI $61.43)
- $61.43 P/E (TTM): 105.73X Cap: $4.40B
- View IHI Profile
- View Questions on IHI
Q: Comments on earnings and if buy, sell or hold. What is happening with medical devices in the current economic environment? Thank you!
Insiders
Share Information
SEC Filings
News and Media